Specifically, GEPIA showed PTGS2 downregulation in bladder, breast, colon, lung, and prostate cancers and upregulation in oesophageal carcinoma, stomach adenocarcinoma, and head and neck squamous cell carcinoma. This evidence concerns the gene PTGS2 and prostate carcinoma.